Currently, COPD-marketed therapy leaders include GSK’s Trelegy Ellipta, which is set to grow in sales to $2.16bn by 2033.

Inhalers for chronic obstructive pulmonary disease (COPD) are a mainstay of treatment. These medications are inhaled through your mouth so they can directly reach your lungs. If your healthcare ...

This highlights the critical need for more therapies to be approved for COPD, as well as for finding a treatment that could become a promising cure for COPD and ultimately reverse the progression of ...

Chronic obstructive pulmonary disease (COPD), an irreversible form of lung disease, is treated with prescription drugs, lifestyle changes, rehabilitation therapies, and surgery in certain cases. The ...

Since this is a progressive disease, having a COPD treatment plan is key to breathing easier in the long term. COPD is a lung condition that restricts airflow, making breathing more difficult.

Opens in a new tab or window “Compared to non-CMR recipients, CMR recipients experienced a considerably higher increase in adherence to COPD medications from 2016 to 2017, and findings with data ...

"FDA greenlights Regeneron’s Dupixent for the treatment of COPD" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.

Dupixent is an “add-on” drug for COPD, meaning patients take it in addition to inhaled medication Dupixent isn’t approved as a stand-alone treatment for COPD. The U.S. Food and Drug ...

Study objectives: To identify the predictors of medication adherence in patients with COPD and contrast the health beliefs, experiences, and behaviors of COPD patients self-reporting good ...

With the latest nod from the US Food and Drug Administration (FDA), Regeneron Pharmaceuticals and Sanofi have expanded the US label of Dupixent (dupilumab) to treat chronic obstructive pulmonary ...